3 AI Healthcare Stocks Retail Investors Are Watching In Australia

Global healthcare spending from governments remains in focus as China directs more public budget towards healthcare and social security. That kind of policy support can help AI healthcare companies find customers who are under pressure to cut costs and improve care quality at the same time. This article looks at 3 transformative AI healthcare stocks from our screener that aim to benefit from this long term shift.

The three stocks below are just a starting sample from this AI healthcare theme, and the full screen surfaces 4 more companies with equally compelling narratives that are not covered in this article. If you want to go straight to the source, use the Transformative Artificial intelligence (AI) Healthcare Stocks screener to identify, compare and analyze the AI healthcare stocks that best fit your thesis.

ImExHS (ASX:IME)

Overview: ImExHS is a Sydney based company that provides cloud based medical imaging software and outsourced radiology services, using its AQUILA, ALULA and ANTEROS platforms and associated imaging datasets to support AI assisted diagnostics across radiology, pathology and cardiology. Its teleradiology and outsourced reporting offerings give hospitals and clinics access to remote specialists while generating curated data that can be used to train and deploy diagnostic AI tools.

Operations: ImExHS generates about A$10 million from Software and A$19 million from Radiology, with revenue currently concentrated in Latin America at about A$29 million.

Market Cap: A$17 million

ImExHS gives you direct exposure to AI assisted imaging in everyday hospital workflows, with its cloud platforms and teleradiology services helping clinicians read scans faster and potentially at lower cost while building datasets for diagnostic tools. The company is currently loss making and relies on funding to support growth, so execution on AI adoption and cash flow remains important. Heavy exposure to Latin American health systems and recent leadership changes around the finance function also add moving parts that investors need to watch. For investors who want AI in healthcare linked to real clinical workflows rather than just concepts, ImExHS is presented as an option for further research.

ImExHS is trying to turn everyday radiology workflows into an AI data engine, yet the real story sits in how its balance sheet and funding runway interact with that plan. Get the ImExHS financial health report

Singular Health Group (ASX:SHG)

Overview: Singular Health Group uses its 3DiCom software and AI in the Cloud platform to turn standard 2D medical scans into interactive 3D models and to layer AI models on top of those images so clinicians can see richer detail, receive automated diagnostic support, and plan treatments more precisely within existing imaging workflows.

Operations: Singular Health Group generates about A$1 million in revenue from the provision and development of medical technology, with a little over A$0.5 million reported from the United States.

Market Cap: A$55 million

Investors looking at AI driven diagnostics may find Singular Health Group interesting because its AI in the Cloud platform is built directly into medical imaging workflows rather than sitting off to the side as a separate tool. That could matter for radiologists who want faster, more consistent reads from 3D models without adding extra steps to their day. At the same time, the company is still early stage with revenue under A$1 million, ongoing losses and less than 1 year of cash runway, which puts funding and execution squarely in focus. For anyone interested in early AI imaging platforms, the key questions are how quickly hospitals adopt the technology and how the balance sheet holds up while that adoption is taking place.

Singular Health Group’s AI in the Cloud story is all about early traction meeting real funding pressure. Get the full picture in the Singular Health Group financial health report and see what the cash runway might be missing.

Artrya (ASX:AYA)

Overview: Artrya is an Australian medical technology company that develops Salix, a cloud based AI platform that reads coronary CT angiography scans to help clinicians detect coronary artery disease, assess plaque and blood flow, and identify patients at higher risk of heart attack so treatment can be tailored earlier and more precisely.

Operations: Artrya currently reports about A$0.03 million in revenue from the development of its AI driven CCTA image analysis technology, all generated in Australia.

Market Cap: A$779 million

Artrya gives you focused exposure to AI in cardiac imaging, with Salix aiming to automate key steps in diagnosing coronary artery disease at a time when CCTA is being used more widely for chest pain assessment. The company is still at an early commercial stage with minimal revenue and a sizeable loss of A$25.18 million for FY 2026. The investment case rests on whether scan volumes, reimbursement for plaque assessment and eventual clearance of the Flow module can support a meaningful earnings shift. A large cash balance and new board experience in imaging and AI workflows help reduce funding and execution concerns, but competitive pressure and clinical trial outcomes remain critical pieces of the story that investors will want to track closely.

Artrya’s push to turn Salix into a standard tool in cardiac imaging could reshape how coronary risk is assessed. Get the analyst forecasts for Artrya and see what the current numbers might be missing

Seeking Fresh Alternatives Beyond Healthcare AI?

Some stock stories move fast and the best entry points often pass before most investors notice. Scan these fresh ideas while they stay under the radar for now and act now.

• Ride potential income momentum by reviewing a curated group of higher yielding companies in the 6 dividend fortresses before payout stories are widely caught by the broader market.
• Spot early shifts in materials demand by tracking producers in the 9 top copper producer stocks while pricing power and project momentum still fly under most watchlists.
• Get ahead of the next infrastructure build cycle by scanning capital heavy operators in the 38 power grid technology and infrastructure stocks before grid upgrade themes appear in every headline.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com